Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kura Oncology (KURA)

Kura Oncology (KURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 676,130
  • Shares Outstanding, K 87,018
  • Annual Sales, $ 53,880 K
  • Annual Income, $ -173,980 K
  • EBIT $ -294 M
  • EBITDA $ -306 M
  • 60-Month Beta 0.23
  • Price/Sales 6.59
  • Price/Cash Flow N/A
  • Price/Book 2.80

Options Overview Details

View History
  • Implied Volatility 214.74% (-147.89%)
  • Historical Volatility 53.66%
  • IV Percentile 95%
  • IV Rank 41.78%
  • IV High 434.09% on 02/04/26
  • IV Low 57.32% on 08/18/25
  • Expected Move (DTE 10) 0.85 (10.84%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 160
  • Volume Avg (30-Day) 656
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 15,548
  • Open Int (30-Day) 15,644
  • Expected Range 6.99 to 8.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.72
  • Number of Estimates 6
  • High Estimate -0.09
  • Low Estimate -0.99
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -227.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.36 +6.56%
on 02/05/26
9.43 -16.86%
on 01/14/26
-1.57 (-16.68%)
since 01/09/26
3-Month
7.36 +6.56%
on 02/05/26
12.49 -37.23%
on 11/14/25
-2.48 (-24.03%)
since 11/10/25
52-Week
5.41 +44.92%
on 04/07/25
12.49 -37.23%
on 11/14/25
-0.95 (-10.81%)
since 02/10/25

Most Recent Stories

More News
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 7.84 (+0.90%)
Record $2.5B Sector Start Spotlights Clinical Oncology Plays

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is surging toward $668.26 billion by 2034 with an 11.50% CAGR as innovative...

ALLO : 1.6900 (unch)
ONCY : 0.8422 (-2.44%)
IMNM : 24.93 (+1.76%)
LLY : 1,025.00 (-1.88%)
KURA : 7.84 (+0.90%)
AMGN : 364.65 (-2.97%)
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

– Launched KOMZIFTI ™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the...

KURA : 7.84 (+0.90%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 7.84 (+0.90%)
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS  – Median duration of complete response...

KURA : 7.84 (+0.90%)
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 7.84 (+0.90%)
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

KURA : 7.84 (+0.90%)
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

SAN DIEGO and TOKYO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced KOMZIFTI™ (ziftomenib),...

KURA : 7.84 (+0.90%)
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1 -mutated AML defined by historically poor outcomes and low...

KURA : 7.84 (+0.90%)
Kura Oncology to Participate in Upcoming Investor Conference

SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 7.84 (+0.90%)

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

3rd Resistance Point 8.33
2nd Resistance Point 8.21
1st Resistance Point 8.02
Last Price 7.84
1st Support Level 7.71
2nd Support Level 7.59
3rd Support Level 7.40

See More

52-Week High 12.49
Fibonacci 61.8% 9.79
Fibonacci 50% 8.95
Fibonacci 38.2% 8.11
Last Price 7.84
52-Week Low 5.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar